Elexacaftor + tezacaftor + ivacaftor

Elexacaftor + tezacaftor + ivacaftor has been studied in 2 papers since 2025: 1 trial and 1 observational study in people; 1 in the past year. The newest paper, Sep 18, 2026: “Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis”.

Intervention

2 papers study it4 findingsUpdated

PubChemPubChemPubChemChEBIChEBIChEBI

See all 2 papers on elexacaftor + tezacaftor + ivacaftor

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries.

“In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”
Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic FibrosisInternational journal of molecular sciences2025doi:10.3390/ijms26146614

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 2 countries
  • Funders: Canada Research Chairs Program and 4 more
  • 2 of 4 findings with company ties
  • Human trial1
  • Humans1

Studies in people

1 study gave elexacaftor + tezacaftor + ivacaftor to people and measured what changed.

What changedDesignPeopleSource

down: Decreases GrimAge2P=0.008

Trialone-year follow-up8 peopletwo (25%) were femalemedian age of 25.4 years (IQR 22.1–28.0)Modulator-naïve pwCFbioRxiv, Sep 18, 2026

What did studies of elexacaftor + tezacaftor + ivacaftor find?

3

Studies of elexacaftor + tezacaftor + ivacaftor measured 3 outcomes: GrimAge2, epigenetic age and lung function.

GrimAge2

downin humans1

1 study
  1. Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in cystic fibrosis (P=0.008).

    “DNAmGrimAge2 age acceleration decreased significantly following ETI (P=0.008; ).”

    Human trialin cystic fibrosisone-year follow-upn = 8

    Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis

    bioRxivPreprint

  2. Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in humans (from 1.92 years to -1.70 years (p=0.008)).

    “DNAmGrimAge2 age acceleration decreased after ETI treatment, from a median of 1.92 years before treatment to -1.70 years after 1 year (p=0.008).”

    Human trial1 yearn = 8

    Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis

    bioRxivPreprint

More on GrimAge2

Epigenetic age

upin humans1

1 study
  1. Elexacaftor + tezacaftor + ivacaftor increases epigenetic age in humans.

    “In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”

    Human trialcystic fibrosis subjects with baseline epigenetic age lower than chronological age; reported as a tendency1 year

    Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis

    International journal of molecular sciences

More on Epigenetic age

Lung function

upin humans1

1 study
  1. Elexacaftor + tezacaftor + ivacaftor improves lung function in humans (cystic fibrosis subjects with baseline epigenetic age lower than chronological age).

    “In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”

    Human trialcystic fibrosis subjects with baseline epigenetic age lower than chronological agelung1 year

    Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis

    International journal of molecular sciences

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 0Nov 2026: 01 paper in 12 months